Results 251 to 260 of about 39,064 (303)

The Use of Biosimilar Epoetins in the Management of Chemotherapy-Induced Anaemia (CIA) in Patients with Breast Cancer: A Subanalysis of the Orheo Study

, 2012
Mauricette Michallet, É. Luporsi, Pierre Soubeyran, H. Albrand   +3 more
openalex   +1 more source

Switching Between Epoetins: A Practice in Support of Biosimilar Use [PDF]

, 2016

core   +1 more source

The Use of Biosimilars in the Management of Chemotherapy-Induced Anaemia (CIA) in Solid Tumours, Lymphoma and Myeloma: the Orheo Study

, 2012
Mauricette Michallet, Pierre Soubeyran, H. Albrand, É. Luporsi   +3 more
openalex   +1 more source

Biosimilars for Australian Dermatologists. [PDF]

Australas J Dermatol
Li GX, Marabani M, Sebaratnam DF.
europepmc   +1 more source

The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome. [PDF]

BioDrugs
Jang JH, Han B, Jung J, Russo P, Kulasekararaj AG.   +4 more
europepmc   +1 more source

Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study. [PDF]

Acta Derm Venereol
Sieborg J, Maul JT, Wu JJ, Loft NN, Skov L, Bryld LE, Rasmussen MK, Dam TN, Bertelsen T, Ajgeiy KK, Thomsen SF, Thyssen JP, Egeberg A, Thein D.   +13 more
europepmc   +1 more source

Clinical and Socioeconomic Burden of Retinal Diseases: Can Biosimilars Add Value? A Narrative Review. [PDF]

Ophthalmol Ther
Hariprasad SM, Holz FG, Asche CV, Issa A, Mora O, Keady S, Rezk MF, Sarocco P, Simoens S.   +8 more
europepmc   +1 more source

Barriers to Biosimilar Approval: Creating Clarity Through the Publication of Product-Class Specific Guidances [PDF]

, 2016
McEnrue, Martin
core  

Evaluating Biosimilar Development Projects: An Analytical Framework Utilizing Net Present Value. [PDF]

Biologics
Ranbhor R, Kulkarni P.
europepmc   +1 more source

Knowledge and Attitudes of Patients with Rheumatoid Diseases towards Biosimilars. [PDF]

Mediterr J Rheumatol
Chantzaras A, Yfantopoulos J, Koutsogianni K.   +2 more
europepmc   +1 more source